CSLCSLLY +6.37%73 EV-to-EBIT is 93.59 as of Jul. 06, 2026, which is 203% above its 10-year median of 30.86. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $50.63 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 367 Biotechnology companies, CSL ranks worse than 90.74% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, CSL's Enterprise Value is $53,251 Mil.
CSL's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $569 Mil. Therefore, CSL's EV-to-EBIT for today is 93.59.
The historical rank and industry rank for CSL's EV-to-EBIT or its related term are showing as below:
CSLLY'
s EV-to-EBIT Range Over the Past 10 Years
Min: 10.21 Med: 30.86 Max: 93.92
Current: 93.59
During the past 13 years, the highest EV-to-EBIT of CSL was 93.92. The lowest was 10.21. And the median was 30.86.
CSLLY's EV-to-EBIT is ranked worse than 90.74% of 367
companies
in the Biotechnology industry
Industry Median: 14.56
vs CSLLY: 93.59
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
CSL's Enterprise Value for the quarter that ended in Dec. 2025 was $67,336 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CSL's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $569 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSL EV-to-EBIT Related Terms
CSL EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for CSL's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CSL's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where CSL's EV-to-EBIT falls into.
CSL's current Enterprise Value is $53,251 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CSL's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $569 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSL (CSLLY) has a EV-to-EBIT of 93.59 as of Jul. 06, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CSL and its competitors. This is 203% above median its historical median of 30.86. Over the past decade, CSL's EV-to-EBIT has ranged from 10.21 to 93.92. According to the industry distribution chart, CSL ranks #333 out of 367 companies in the Biotechnology industry, placing it in the top 90.7%.
Is CSL's EV-to-EBIT too high?
CSL's current EV-to-EBIT of 93.59 is 203% above median its 10-year median of 30.86. Over the past 10 years, this metric has ranged from a low of 10.21 to a high of 93.92. The Biotechnology industry median EV-to-EBIT is 14.56. CSL's value of 93.59 is 542.8% above this industry median. Based on the distribution chart, CSL ranks #333 out of 367 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #333 out of 367 companies for EV-to-EBIT. This places CSL in the lower half of its industry. The industry median EV-to-EBIT is 14.56. CSL's value of 93.59 is 542.8% above this benchmark. Historically, CSL's own EV-to-EBIT has ranged from 10.21 to 93.92 over the past decade. While the company's 10-year median is 30.86 vs. the industry median of 14.56, CSL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.56, based on 367 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current EV-to-EBIT of 93.59 is 542.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CSL and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current EV-to-EBIT is 93.59, which is 203% above median its own 10-year median of 30.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $50.63, compared to a current price of $21.79 — trading 57% below its estimated fair value. The current EV-to-EBIT is 93.59, which is 203% above median its 10-year median of 30.86 and 542.8% above the Biotechnology industry median of 14.56. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For CSL (CSLLY), the current EV-to-EBIT is 93.59 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $21.79 is trading 57% below its estimated GF Value™ of $50.63.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
EV-to-EBIT: 93.59 (203% above median its 10-year median of 30.86)
GF Value™: $50.63 vs. price of $21.79 (57% below fair value)
Industry Position: 542.8% above the Biotechnology median (#333 of 367)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CSLLY
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
